Tumor Delivery of Chemotherapy Combined with Inhibitors of Angiogenesis and Vascular Targeting Agents by Marta Cesca et al.
REVIEW ARTICLE
published: 01 October 2013
doi: 10.3389/fonc.2013.00259
Tumor delivery of chemotherapy combined with inhibitors
of angiogenesis and vascular targeting agents
Marta Cesca1, Francesca Bizzaro1, Massimo Zucchetti 2 and Raffaella Giavazzi 1*
1 Laboratory of Biology and Treatment of Metastases, Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
2 Laboratory of Cancer Pharmacology, Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
Edited by:





Matteo Bellone, San Raffaele
Scientific Institute, Italy
*Correspondence:
Raffaella Giavazzi , Laboratory of
Biology and Treatment of Metastases,
Department of Oncology,
IRCCS-Istituto di Ricerche
Farmacologiche “Mario Negri”, Via La
Masa 19, 20156 Milan, Italy
e-mail: raffaella.giavazzi@marionegri.it
Numerous angiogenesis-vascular targeting agents have been admitted to the ranks
of cancer therapeutics; most are used in polytherapy regimens. This review looks at
recent progress and our own preclinical experience in combining angiogenesis inhibitors,
mainly acting on VEGF/VEGFR pathways, and vascular targeting agents with conventional
chemotherapy, discussing the factors that determine the outcome of these treatments.
Molecular and morphological modifications of the tumor microenvironment associated
with drug distribution and activity are reviewed. Modalities to improve drug delivery and
strategies for optimizing combination therapy are examined.
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INTRODUCTION
Recognition of the multi-compartment nature of the tumor
microenvironment has challenged the conventions of anticancer
therapy, giving rise to a radically different approach toward the
discovery of new treatments. Historically aimed at killing tumor
cells (cytotoxic agents), the search now seeks to identify novel“bio-
logicals,” that selectively target not only the cancer cell, but also the
tumor stroma.
Angiogenesis – the development of new vasculature – is
required for tumor growth, invasion, and metastatic dissemina-
tion, hence the rationale for anti-angiogenic therapy (1). Numer-
ous angiogenesis-targeting agents have been admitted to the ranks
of cancer therapeutics (2). Drugs targeting the tumor vasculature
have been developed and have shown efficacy in preclinical models
and in some clinical trials (1–3).
The most validated anti-angiogenic strategy to prevent tumor
vessel formation targets the vascular endothelial growth fac-
tor (VEGF) axis. VEGF can be blocked directly, with the anti-
body bevacizumab (Avastin®), or, among others, with the VEGF-
trap (Aflibercept®), an engineered soluble VEGF receptor able
to bind VEGF as well as platelet growth factor (PLGF) (4),
or indirectly by inhibiting receptor activity with antibodies or
small-molecule tyrosine kinase receptor inhibitors (RTKIs). Suni-
tinib (Sutent®), sorafenib (Nexavar®), and pazopanib (Votri-
ent®) have been approved for different tumor types (5). An
alternative strategy is to selectively destroy the existing vas-
culature with vascular disrupting agents (VDA) (6–8). VDA
cause a pronounced and rapid shutdown of blood flow to
solid tumors, leading to tumor necrosis and death. Small mole-
cules, flavonoids (DMXAA), and tubulin-binding agents (Ca4P,
ZD6126, Ave8062, Oxi4503), have entered into Phase II–III
studies.
Inhibition of a single target or pathway is of limited benefit
for cancer patients (9). The primary clinical use of bevacizumab
is combined with chemotherapy, as only the combination sig-
nificantly prolonged overall survival in patients with metastatic
colorectal cancer (CRC) (10) and recurrent/advanced non-small
cell lung cancer (NSCLC) (11), or extended progression-free
survival in patients with advanced ovarian cancer (12–14) and
renal cell cancer (15). Unlike bevacizumab, the multitargeted
profile of RTKIs makes them active as single agents, and any
clear advantage in combination with chemotherapy has yet to be
demonstrated (16).
The mechanism by which anti-angiogenic agents increase the
efficacy of chemotherapy is not yet clear. An angiogenesis inhibitor
combined with chemotherapy affects multiple compartments,
depriving the tumors of nutrients and oxygen (i.e., anti-vascular
and anti-angiogenic effect), and killing highly proliferative tumor
cells (i.e., cytotoxic effect) (17). In terms of drug delivery this
sounds paradoxical since the anti-angiogenic therapy, by modi-
fying the tumor vasculature, potentially impairs the delivery of
cytotoxic drugs (18).
The tumor microenvironment has an abnormal vasculature,
structurally and functionally (increased vessel permeability, dilata-
tion and tortuosity, reduced pericyte coverage, and abnormal
basement membranes), mainly because of an imbalance between
pro- and anti-angiogenic factors (19, 20). As a consequence, tumor
blood flow is impaired and this, together with compression of the
blood vessel by the growing cancer, results in high interstitial fluid
pressure (IFP), hypoxic regions within the tumor, and ultimately
reduced drug delivery (21, 22).
Anti-VEGF, and more in general anti-angiogenesis agents,
modify the tumor microenvironment; abnormal microvessels are
destroyed and the remaining vessels are remodeled (2). These
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changes, that led Jain and coworkers to formulate the hypothesis of
“vascular normalization,”should lead to a transient increase in vas-
cular patency, a drop in IFP and alleviation of hypoxia, providing
a “window of opportunity” for the delivery of drugs, with better
therapeutic outcome. For reviews on tumor microenvironment
normalization see Jain (23, 24). The normalization hypothesis
offers a solution to the paradox that some angiogenesis inhibitors
are efficacious when combined with chemotherapy.
Whether these morphological changes are accompanied by
functional modifications, such as improved drug delivery, is still
debated (25–27). Current attempts at combination treatments are
often empirical, though rational protocols are needed that take
account of drug pharmacokinetics, and their metabolic interac-
tions and mechanism of action, as well as the biological char-
acteristics of the tumor microenvironment (28). Careful dosing,
scheduling, and sequencing of treatments, to avoid possible nega-
tive interactions and side effects, become essential to optimize the
efficacy of combinations (7, 29). Optimization requires reliable,
robust end points to monitor the activity of the combination.
This review focuses on recent progress, and our own preclinical
experience in combining angiogenesis inhibitors/vascular target-
ing agents with conventional chemotherapy. Molecular, morpho-
logical and functional modifications of the tumor microenviron-
ment related to drug distribution and activity are reviewed and, we
examine some modalities to improve drug delivery and strategies
for the optimization of combination therapy.
COMBINATION WITH BEVACIZUMAB
Bevacizumab is a humanized monoclonal antibody that targets
VEGF (30). It has been approved, in combination with chemother-
apy, for a number of malignancies, including colon, lung, and ovar-
ian (in Europe) cancer (10–12), and for kidney cancer combined
with interferon-gamma.
According to the hypothesis of vessel “normalization,” Jain and
coworkers showed in a number of tumor models transplanted in
the cranial window or in the dorsal skinfold chamber of mice, that
vessels begun to function better when treated with a neutralizing
antibody anti-VEGF, possibly enhancing delivery of chemother-
apy (31). Next, the duration of the “normalization window” was
associated with alleviation of hypoxia, which plays a role in drug
resistance and tumor progression. Radiotherapy was also more
effective when administered during the normalization window
(32). However, while preclinical studies have reported morpholog-
ical and functional changes in the tumor vasculature after blocking
VEGF, studies on drug delivery after anti-angiogenesis treatment
are scanty. A tendency to a higher CPT11 concentration, that
paralleled increased tumor perfusion, was observed in a colon car-
cinoma growing in nude mice after VEGF-blocking therapy. This
suggested an increase in transport capability by vessels surviving
anti-angiogenic treatment that compensated the reduction in the
number of patent blood vessels (33).
The main concern about the “normalization window” is the
limited time in which it occurs. As an example, orthotopic neu-
roblastoma xenografts treated with bevacizumab were evaluated
at serial time points for treatment-associated changes in intra-
tumoral vascular physiology, penetration of chemotherapy, and
efficacy of combination therapy. After bevacizumab, there was a
progressive decrease in tumor microvessel density, with a rapid,
sustained fall in tumor vessel permeability and tumor IFP, while
tumor perfusion (mirrored by drug delivery) improved. Unfortu-
nately these changes were short-lasting; the improvement in drug
delivery was observed only for a few days after bevacizumab, but
not when both drugs were given concomitantly. Although the com-
bination was always superior to single-agent treatment, sequential
treatment within the “normalization window” gave no significant
advantage over concomitant treatment (34).
Our laboratory found that bevacizumab in combination with
chemotherapy delayed tumor progression in mice bearing ovar-
ian carcinoma xenografts, significantly prolonging survival (35).
We observed a clear effect of bevacizumab on vessel morphol-
ogy toward a “normalization” phenotype (e.g., decrease in vessel
number, increase in pericyte coverage), but this was not related
to increased drug uptake into tumor. While these findings do not
explain the better outcome with the combination, we hypothesize
that after bevacizumab, distribution of the cytotoxic drug might
be better in more vital and actively proliferating areas of the tumor.
Studies are in progress using Imaging Mass Spectrometry to clar-
ify the spatial distribution of drugs into the tumor tissue after
angiogenesis inhibitors (36).
Similar considerations can be extended to the combination
of bevacizumab with large molecules, such as antibodies. For
example reduced uptake of trastuzumab (a monoclonal antibody
directed against HER-2/neu) after bevacizumab was observed in
HER-2 expressing breast cancer xenografts. This was presumably
due to tumor blood flow and vascular permeability reduction
which contribute to the changes of trastuzumab pharmacokinetics
(37). However the combination of bevacizumab with trastuzumab
has given promising results in breast cancer patients (38).
Few clinical studies report the effects of anti-angiogenic ther-
apy on drug uptake. One of the first pointers to the anti-vascular
effect of bevacizumab in a clinical setting, came from a phase I
study, in which patients with non-metastatic CRC were given a
single infusion of bevacizumab, concomitantly with neo-adjuvant
chemotherapy with 5-fluorouracil. Twelve days after its infusion,
bevacizumab reduced tumor blood perfusion and vascular vol-
ume, accompanied by decreases in microvessel density, lower
IFP, and increased pericyte coverage, confirming the drug’s anti-
vascular and normalizing effects in human tumors (39). Vessel
permeability, assessed as computed tomography (CT) contrast
agent extravasation, and fluorodeoxyglucose (FDG) uptake into
the tumor during positron emission tomography (PET) scans,
did not change, indirectly showing cytotoxic drug uptake was not
affected. PET scan 6 weeks after the bevacizumab and chemother-
apy showed reduced FDG uptake than in previous scans, in
accordance with the “temporary” duration of the normalization
window (39).
To elucidate the effects of angiogenesis inhibitors on drug
delivery, a recent study used PET to investigate bevacizumab
combined with (11C)docetaxel in NSCLC patients. Bevacizumab
reduced perfusion and the net influx rate of docetaxel, shortly
after its administration, and for several days afterward, showing
no substantial improvement in drug delivery into tumors. Inter-
estingly,bevacizumab prolonged systemic drug exposure, reducing
plasma clearance, and causing more homogeneous intratumoral
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distribution, as a result of some normalization of tumor vascula-
ture (40). These findings indicate that anti-VEGF therapy not only
does not improve tumor drug delivery, but rather has an oppo-
site effect. The authors also suggested that the anti-angiogenic
drug might be given after the anticancer agent, as the immediate
decrease in tumor perfusion should reduce the clearance of drugs
from tumors.
Thus, there is currently a large body of evidence indicating
that agents such as bevacizumab cause vascular normalization,
but whether this phenomenon favors or not drug penetration into
tumors remains unclear. Studies in humans highlight the impor-
tance of drug scheduling and call for further studies to optimize
combination modalities (41).
COMBINATION WITH RECEPTOR TYROSINE KINASE
INHIBITORS
A large number of small molecules that are multi-receptor RTKI,
have progressed through clinical development (5). Unlike beva-
cizumab, the RTKIs have antitumor activity in monotherapy, and
are rarely used in combination with chemotherapy in clinical prac-
tice, as no clear benefit has been reported (16). Clinical data on
chemotherapy uptake after RTKIs are lacking.
The partial advantage we have observed, in preclinical mod-
els combining sunitinib (VEGFRs, PDGFRs, and c-Kit inhibitor)
with chemotherapy (42) raises the question whether these mole-
cules differ from bevacizumab in their anti-angiogenic actions and
herein in their ability to facilitate drug distribution and activity.
Several preclinical studies have exploited RTKIs in combination
with chemotherapy aimed to study drug interaction and modi-
fication of the tumor/stroma compartment which can ultimately
affect drug distribution. RTKIs often give rise to increased hypoxia
and decreased drug uptake [for review see Ref. (43)].
For example, the small-molecule axitinib (VEGFRs, PDGFR,
and c-KIT inhibitor) affected tumor vasculature as the number of
blood vessels decreased, and hypoxia increased (44, 45). In combi-
nation with cyclophosphamide, this led to decreased delivery of its
metabolite (4-OH-CPA) into the tumor, with the consequence of
limited antitumor activity, and no tumor regressions (44). Inter-
estingly, the anti-vascular activity of axitinib, could be turned to
a therapeutic advantage if cyclophosphamide was injected intra-
tumor: axitinib slowed leakage of 4-OH-CPA, increasing its reten-
tion (46). Thus drug retention, as consequence of anti-angiogenic
therapy, can be exploited for combination with drugs injected
intra-tumor or for systemic delivery of pro-drugs directly activated
in the tumor (46). (See also combination with VDA below).
Some years ago we studied the combination of SU6668 (a
first-generation VEGFR-2, FGFR, and PDGFRβ inhibitor) with
paclitaxel on ovarian cancer xenograft models (47, 48). The com-
bination affected tumor burden and prolonged overall survival,
depending on the tumor’s sensitivity to paclitaxel (less efficient on
the resistant tumor), the treatment regimen (less active, though
less toxic at a metronomic schedule) and the tumor burden at
the beginning of treatment (less active on large tumors). Though
SU6668 alone and in combination affected tumor vascular density
(48), there was no improvement in paclitaxel uptake. The limited
advantage given by SU6668 added to paclitaxel on the resistant
tumor compared to the sensitive one indicated that angiogenesis
inhibitors and cytotoxic agents act on the tumor and host com-
partments independently, with some combined effects on the same
compartment (the host), as paclitaxel is a strong vascular targeting
drug (49).
These initial findings prompted us to investigate morpholog-
ical and functional changes of the tumor vasculature induced by
the RTKI vandetanib (VEGFR2, EGFR, and RET inhibitor), and
its effect on intratumoral delivery and the antitumor activity of
paclitaxel (27). In line with previous observations, the combina-
tion of vandetanib plus paclitaxel had greater antitumor activity
than the single agent treatments (50). However, changes in vascular
morphology and function (normalization) induced by vandetanib
were not associated with any increase in paclitaxel delivery into the
tumor. In fact, our results showed that the antitumor activity of
vandetanib combined with paclitaxel is at least partly dependent
on the drug sequence. In mice pretreated with vandetanib, pacli-
taxel delivery decreased, reflecting a decrease in tumor perfusion,
assessed as Hoechst 33342 levels, an indicator of vascular perfusion
(27). The decrease in uptake of paclitaxel after vandetanib was par-
ticularly evident at an early time point (1 h after paclitaxel) as levels
were similar later (24 h after paclitaxel). As plasma data excluded
reduced drug availability, this might have been due to less efficient
paclitaxel penetration in the more poorly perfused vandetanib-
treated tumor, followed by longer retention for the same reason.
Vandetanib impaired paclitaxel uptake already after 1 day of treat-
ment, with maximum effect after 5 days. On stopping vandetanib,
paclitaxel uptake by the tumor was restored, indicating that van-
detanib’s effect on drug distribution in tumors is reversible as it is
the “normalization” phenomenon (27).
We have observed reduced paclitaxel delivery into the tumor
with no change in systemic pharmacokinetics, in combina-
tion experiments with different RTKIs (sunitinib and the dual
inhibitors of VEGFR2 and FGFR2, brivanib and E-3810), despite
the improved antitumor activity. E-3810 reduced vessel num-
ber, and induced tumor microenvironment modifications which
ultimately lead to remodeling of the extracellular matrix (51).
At variance, inhibition of PDGFR signaling with an increase
in taxol uptake into the tumor and greater therapeutic effect have
been described (52). Imatinib,beside its original selectivity for Bcr-
Abl tyrosine kinase, affects PDGFRβ, lowers IFP and microvessel
density, and improves tumor oxygenation, consequently increas-
ing the tumor concentration of small molecules such as docetaxel,
or bigger ones such as liposomal doxorubicin (53).
One possible explanation for these controversial findings could
be the different inhibitors of angiogenesis used in those study. Also
the dose of the anti-angiogenic drug, might play an important role,
as a too high dose can cause too rapid vessel pruning and not favor
drug delivery and anticancer effects (24). The effect of different
doses of RTKI on vessel morphology and functionality was not
explored in the above study.
In the light of these considerations, we suggest that the com-
bination of RTKI with chemotherapy is feasible. A better use of
pharmacodynamics and pharmacokinetics, might help to maxi-
mize the effect and avoid negative interactions of RTKI combined
with chemotherapy. Recently we have shown that the addition of
certain chemotherapeutics to sunitinib is able to counteract the
unwonted negative effect on tumor metastasization (42).
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COMBINATIONS WITH OTHER ANGIOGENESIS INHIBITORS
The first combination modalities based on anti-angiogenic com-
pounds used TNP-470, an inhibitor of methionine aminopepti-
dase, an essential enzyme for endothelial cell proliferation. TNP-
470 potentiated the antitumor activity of cytotoxic therapeutics,
increasing their biodistribution into tumor tissue, an effect that
was sufficient per se to account for the greater delay in tumor
growth (54).
A number of molecular targets, alternatives to VEGF/VEGFR
and related growth factors, implicated in vascular remodeling,
are worth considering for the development of novel therapeutic
modalities.
Semaphorin 3A (Sema3A) is expressed in endothelial cells,
where it serves as an endogenous inhibitor of angiogenesis, and
is lost during tumor progression. Its long-term re-expression at
a later stage of carcinogenesis stably normalized the tumor vas-
culature in transgenic mouse tumor models and impaired tumor
growth (55). In an accompanying study the authors showed there
were larger amounts of doxorubicin in Sema3A-treated tumors,
than controls, so Sema3A re-expression substantially extends the
normalization window of tumor blood vessels and improves the
delivery efficiency of chemotherapeutic drugs (56).
Selective killing of tumor neovasculature with an antibody
directed against tumor vascular endothelial VE-cadherin, conju-
gated with an α-particle-emitting isotope generator, caused vas-
cular remodeling, increased tumor delivery of chemotherapy, and
reduced tumor growth. Interestingly, the effect was seen when
chemotherapy was scheduled several days after the anti-vascular
therapy. The authors pointed out that after depletion of the major-
ity of vessels, the remaining ones appear more mature, so small-
molecule drugs more homogeneously distribute and accumulate
better, as reflected in the improvement of antitumor activity (57).
COMBINATION WITH VASCULAR TARGETING AGENTS
Therapeutic vascular targeting agents comprise small molecules,
mainly tubulin-binding agents, flavonoids, antagonists of junc-
tional proteins intended to selectively target the tumor vasculature
(VDA), and compounds that target proteins expressed selectively
on tumor vasculature used to deliver bioactive molecules (6, 58,
59). VDA induce morphologic changes in endothelial cells, trig-
gering a cascade of events that results in rapid reduction of blood
flow, and vessel occlusion, with subsequent tumor cell death. The
hallmark of VDA action is the induction of massive central necro-
sis of tumor tissues, leaving a rim of viable, actively proliferating
cells at the periphery of the lesion. The ability of these proliferating
cells to repopulate the tumor explains the limited activity of these
agents as monotherapy, but also justifies their use in combination
with cytotoxic drugs. IFP levels dropped rapidly after VDA (60)
suggesting that if they are used appropriately in conjunction with
other drugs the efficacy of treatment may be enhanced. The benefit
from such combinations should be complementary, with the VDA
acting primarily on the tumor vasculature, and the chemotherapy
mainly affecting proliferating tumor cells.
A number of VDA have reached the clinical stage (61). Their
effects on tumor vasculature have obvious implications in the
design of combination treatments given their possible interfer-
ence with distribution of the cytotoxic drug (62). The sequence
of administration has to take into account that the vessel shut-
down induced by the VDA given after the cytotoxic compound
would trap it within the tumor, at the same time preventing the
possible VDA-induced impairment of drug distribution in the
tumor. Conversely, the opposite schedule, i.e., the VDA before
the cytotoxic drug, might generate favorable conditions for its
activity because the highly proliferating cells at the periphery of
VDA-treated tumors are an ideal target for cytotoxic drugs (7).
We administered the VDA ZD6126 followed by paclitaxel 24–
72 h later; this combination had greater antineoplastic activity than
each single agent, leading to complete tumor remissions (63). That
study showed a significant increase in proliferative activity at the
tumor periphery after ZD6126, concomitant with the induction of
massive necrosis. It is therefore conceivable that pretreatment with
ZD6126 affects the inner part of the tumor, while chemotherapy
targets the actively proliferating cells in the viable peripheral rim.
The pharmacokinetics of paclitaxel in the ZD6126-treated tumor
indicated greater accumulation in the peripheral rim of the tumor
than the interior part.
The actual target in the tumor periphery might include
endothelial cells, thus providing a rationale for combining a VDA
with an anti-angiogenic agent (64). Rapid mobilization of circu-
lating progenitor endothelial cells which home into the viable rim
surrounding the necrotic area was reported in a tumor model of
mice treated with the VDA OXi-4053, which was associated with
the tumor vasculature (65).
THE DUAL FACE OF PACLITAXEL
Paclitaxel is one of the most widely used cytotoxic drugs, employed
in the treatments of several neoplasms. This tubulin-binding agent
promotes microtubule polymerization (at high concentrations)
and impairs microtubule dynamics (at low concentrations), ulti-
mately affecting mitosis, as well as other microtubule-dependent
cell functions (66). The anticancer activity of paclitaxel extends
beyond its cytotoxicity against tumor cells, since paclitaxel, and
the tubulin-binding agents in general, also targets tumor stroma
and vasculature inhibiting endothelial cell functions related to
angiogenesis, at lower concentrations than those required for the
cytotoxic activity (7, 49).
We have shown by in vivo optical, and dynamic contrast
enhanced (DCE)-MRI imaging that paclitaxel can modify cer-
tain tumor vessel functions related to vascular perfusion and
permeability (fractional plasma volume, fPV, and volume trans-
fer coefficient, kTrans) (67). This was associated with increased
tumor uptake of the antibody F8 (which selectively recognize
perivascular EDA-fibronectin) conjugated to interleukin 2 (F8-
IL2) (68). The use of antibody-based delivery of therapeutic agents
in cancer therapy is beyond our scope and is covered by excellent
reviews (59, 69).
Herein paclitaxel given before, but not after, F8-IL2 potenti-
ated the latter’s antitumor activity on EDA-Fn expressing human
melanoma xenografts. We attributed this to increased vascular
permeability and perfusion at the tumor site, as the area perfused
by Hoechst 33342 was larger in paclitaxel treated tumors than
controls.
Although the mechanism of this effect of paclitaxel is far from
clear, our findings are in line with other reports. Jain and coworkers
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proposed that taxane-induced tumor cell apoptosis reduced the
IFP generated by neoplastic cell proliferation (solid stress) and
decompressed tumor blood vessels. The increase in vessel diameter
suggests that taxanes might improve tumor response by increas-
ing the vascular surface area for the delivery of therapeutics (70).
Paclitaxel and docetaxel lowered IFP and significantly increased
albumin extravasation regardless of their cytotoxic activity, sug-
gesting that these effects might be taxane-specific and related to
the drugs’ pharmacodynamics (71).
The translational potential of these findings is substantiated by
clinical studies. In breast cancer patients treated with neo-adjuvant
chemotherapy, paclitaxel lowered IFP, and increased oxygenation
(72); this suggests that at least these tumors would be best treated
first with paclitaxel to reduce IFP and increase pO2 in order to
improve the delivery of subsequent therapy, particularly of large
molecules such as antibodies. However, the theory of solid stress in
tumors only partially explains the biologic mechanisms by which
taxanes boost the activity of combination therapy.
Two mechanisms have been proposed to explain the activity
of co-administration of albumin-bound paclitaxel (Abraxane®,
nab-paclitaxel) and gemcitabine in patients with pancreatic cancer
(73). In a first study nab-paclitaxel increased the intratumoral con-
centration of gemcitabine in a mouse model of pancreatic ductal
adenocarcinoma (PDA) (74). In a second study the nab-paclitaxel
co-administered with gemcitabine caused tumor regression, due
to a different mechanism, as gemcitabine was stabilized in the
tumor by paclitaxel’s reduction in the levels of cytidine deaminase,
the enzyme primarily responsible for gemcitabine metabolization,
with no changes in overall drug delivery (75).
CONCLUSION
The inhibition of tumor growth by drugs affecting the tumor vas-
culature has been achieved in preclinical and clinical studies. The
combination of an angiogenesis inhibitor, namely bevacizumab,
with chemotherapy, showed a benefit in patients with advanced
disease, leading to increased interest in developing more effec-
tive ways to combine anti-angiogenic/vascular targeting agents
with conventional chemotherapy. Morphological changes in the
tumor microenvironment and vasculature are widely observed
after angiogenesis inhibitors. However, the balance between low-
ering tumor microvessel density, impairing their function, and
reducing/increasing drug uptake needs to be carefully con-
sidered in choosing the doses and schedule for combination
settings.
Some preclinical studies have reported functional improve-
ment in tumor blood perfusion after angiogenesis inhibitors, with
increased tumor exposure to cytotoxic drugs. However, in other
studies tumor vascular patency decreased, and hypoxia increased,
with impaired cytotoxic drug uptake. The causal relationships
between the effect on the microvasculature, the IFP reduction,
and the improved trans-vascular transport are still not completely
clear.
Nevertheless the combination of angiogenesis inhibitors with
chemotherapy is almost always superior to single-drug treatment,
indicating the beneficial effect of tumor cell starvation induced
by angiogenesis inhibition. The order of administration of the
two types of agents – anti-vascular and antitumor – is critical for
a successful outcome and has far-reaching impact on the design
of combination therapy. Careful optimization of drug schedul-
ing and dosage is essential to maximize tumor response. Robust
tumor pharmacodynamics and pharmacokinetics could help in
fine-tuning drug timing and sequences so as ultimately to achieve
a better outcome.
Monitoring the activity of angiogenesis inhibitors/vascular tar-
geting agents is a significant practical challenge in the clinical
setting, where non-invasive procedures such as imaging analysis
and the detection of soluble biomarkers can be used to optimize
the administration and determine the efficacy of combination
regimens in patients.
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